跳转至内容
Merck
CN
  • Enhancing crystalline properties of a cardiovascular active pharmaceutical ingredient using a process analytical technology based crystallization feedback control strategy.

Enhancing crystalline properties of a cardiovascular active pharmaceutical ingredient using a process analytical technology based crystallization feedback control strategy.

International journal of pharmaceutics (2012-03-28)
Ali N Saleemi, Gerry Steele, Nicholas I Pedge, Anthony Freeman, Zoltan K Nagy
摘要

Pharmaceutical regulatory bodies require minimal presence of solvent in an active pharmaceutical ingredient (API) after crystallization. From a processing point of view bigger crystals with minimal agglomeration and uniform size distribution are preferred to avoid solvent inclusion and for improved downstream processing. The current work addresses these issues encountered during the production of the potential anti-arrhythmic cardiovascular drug, AZD7009. This paper demonstrates that by applying the automated direct nucleation control (ADNC) approach problems with agglomeration and solvent inclusion were resolved. This model free approach automatically induces temperature cycles in the system, with the number of cycles, temperature range and adaptive heating and cooling rates determined to maintain the number of particles in the system, as measured by a focused beam reflectance measurement (FBRM) probe, within a constant range during the crystallization. The ADNC approach was able to produce larger and more uniform crystals and also removed the residual solvent trapped between the crystals compared to the typical crystallization operation using linear cooling profile. The results illustrate the application of process analytical technologies, such as FBRM and ATR-UV-vis spectroscopy, for the design of optimal crystallization operating conditions for the production of pharmaceuticals, and demonstrate that the ADNC approach can be used for rapid crystallization development for APIs exhibiting problems with agglomeration and solvent inclusion.

材料
货号
品牌
产品描述

Sigma-Aldrich
二异丙基醚, puriss. p.a., ≥98.5% (GC)
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mL
请联系客服了解存货情况
¥1,649.70
10 x 0.75 mL
预计发货时间 2025年3月03日
详情...
¥2,396.87
25 mL
预计发货时间 2025年3月03日
详情...
¥4,878.66
Sigma-Aldrich
二异丙基醚, ReagentPlus®, 99%, contains either BHT or hydroquinone as stabilizer
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mL
请联系客服了解存货情况
¥1,649.70
10 x 0.75 mL
预计发货时间 2025年3月03日
详情...
¥2,396.87
25 mL
预计发货时间 2025年3月03日
详情...
¥4,878.66
Sigma-Aldrich
二异丙基醚, contains either BHT or hydroquinone as stabilizer, ACS reagent, ≥99.0%
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mL
请联系客服了解存货情况
¥1,649.70
10 x 0.75 mL
预计发货时间 2025年3月03日
详情...
¥2,396.87
25 mL
预计发货时间 2025年3月03日
详情...
¥4,878.66
Sigma-Aldrich
二异丙基醚, anhydrous, 99%, contains either BHT or hydroquinone as stabilizer
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mL
请联系客服了解存货情况
¥1,649.70
10 x 0.75 mL
预计发货时间 2025年3月03日
详情...
¥2,396.87
25 mL
预计发货时间 2025年3月03日
详情...
¥4,878.66
Supelco
二异丙基醚, analytical standard
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mL
请联系客服了解存货情况
¥1,649.70
10 x 0.75 mL
预计发货时间 2025年3月03日
详情...
¥2,396.87
25 mL
预计发货时间 2025年3月03日
详情...
¥4,878.66